NCT07460180 2026-03-10
PROOV
The Netherlands Cancer Institute
Phase 1/2 Recruiting
Clinical Trials
15 trialsNCT03085147 2026-02-12
A Dye for the Detection of Cancer of the Tongue and Mouth
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
NCT02813135 2026-01-16
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT04711824 2025-12-23
SOLARA
Hoosier Cancer Research Network
Phase 1/2 Recruiting
NCT03212742 2025-12-04
OLA-TMZ-RTE-01
Centre Francois Baclesse
Phase 1/2 Active not recruiting
NCT02755844 2025-10-02
ENDOLA
Hospices Civils de Lyon
Phase 1/2 Completed
NCT05405309 2025-06-03
CORONADO CLL
University of Utah
Phase 1/2 Terminated
NCT02571725 2025-05-23
PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer
New Mexico Cancer Research Alliance
Phase 1/2 Active not recruiting
NCT03594396 2025-04-17
Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer
Seoul National University Hospital
Phase 1/2 Active not recruiting
NCT04826198 2024-12-05
REVOCAN
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Terminated
NCT01513174 2024-06-28
GOAL
Spanish Lung Cancer Group
Phase 1/2 Completed
NCT06217757 2024-05-13
Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
Sichuan University
Phase 1/2 Recruiting
NCT06298084 2024-03-29
ICARUSBREAST02
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT02446704 2022-02-07
Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy
Massachusetts General Hospital
Phase 1/2 Unknown
NCT01650376 2018-03-23
Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer
Swedish Medical Center
Phase 1/2 Unknown